Tamoxifen for the primary prevention of breast cancer: A review and critique of the concept and trial

Epidemiologic Reviews

Volumn 15, Issue 1, 1993, Pages 233-243

  Bush, Trudy L ^a   Helzlsouer, Kathy J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART PROTECTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMAN; MIDDLE AGE; RESEARCH DESIGN; TAMOXIFEN;

EID: 0027290493     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a036110     Document Type: Article

References (37)

1. Morrison AS. Screening for cancer of the breast. Epidemiol Rev 1993; 15:244-55.
2. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
3. Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991, 83:1450-9.
4. Powles TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 1992;340: 1145-7.
5. Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980; 16:239-51.
6. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the jv-nitrosomethylurea- induced rat mammary carcinoma model. Cancer Res 1987, 47:4020-4.
7. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.
8. National Surgical Adjuvant Breast and Bowel Project (NSABP). NSABP Protocol P-l: a clinical trial to determine the worth of tamoxifen for preventing breast cancer. Pittsburgh, PA: National Surgical Adjuvant Breast and Bowel Project, January 24, 1992. (Chairman: Dr. Bernard Fisher, University of Pittsburgh).
9. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25: 127-205.
10. Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer with tamoxifen: an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990;26:680-4.
11. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
12. Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984; 53:853-7.
13. Fentiman IS, CalefTi M, Rodin A, et al. Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 1989, 60:262-4.
14. Breast Cancer Trial Committee, Scottish Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987, 2:171-5.
15. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
16. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1: 117-20.
17. Fugh-Berman A, Epstein S. Tamoxifen: disease prevention or disease substitution? Lancet 1992; 340:1143-5.
18. DeGregorio MW. Is tamoxifen chemoprevention worth the risk in healthy women? J N1H Res 1992; 4(9):84-7.
19. Raloff J. Tamoxifen quandary: promising cancer drug may hide a troubling dark side. Sci News 1992;141:266-9.
20. Tamoxifen trial controversy. (News and Commentary). Lancet 1992;339:735.
21. Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842-7.
22. Pavlidis NA, Petris C, Briassoulis E. et al. Clear evidence that long-term low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992;69: 2961-4.
23. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978;62:315-20.
24. Ashford AR, Donev I, Tiwati RP, et al. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61:33-5.
25. Vinding T, Nielsen NV. Retinopathy caused by treatment with tamoxifen in low dose. Acta Ophthalmol (Copenh) 1983;61:45-50.
26. Bentley CR, Davies G, Aclimondos WA. Tamoxifen retinopathy, a rare but serious complication. BMJ 1992, 304;495-6.
27. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-4.
28. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. ClinChem 1988;34:B60-70.
29. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991, 303:435-7.
30. Magriples U, Naftolin F, Schwartz PE, et al. Highgrade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11: 485-90.
31. Meeting of the Oncologic Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, September 21, 1992. (Transcript available from C.A.S.E.T. Associates, 3927 Old Lee Highway, Fairfax, VA 22030).
32. Kannel WB, Abbott RD. Incidence and prognosis of myocardial infarction in women: The Framingham Study. In: Eaker ED, Packard B, Wenger NK, et al, eds. Coronary heart disease in women: proceedings of an N.I.H. workshop. New York: Haymarket-Doyma, Inc, 1987:208-14.
33. Saphner T, Tromey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9:286-94.
34. Hendrick A, Subramanian VP. Tamoxifen and thromboembolism. JAMA 1980, 243:514-15.
35. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984;68:887-9.
36. Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis. Lancet 1978, 2:946-7.
37. Ching CK, Smith PG, Long RG. Tamoxifenassociated hepatocellular damage and agranulocytosis. (Letter). Lancet 1992;339:940.